190 related articles for article (PubMed ID: 32045362)
21. Estrogen activates pyruvate kinase M2 and increases the growth of TSC2-deficient cells.
Lu Y; Liu X; Zhang E; Kopras EJ; Smith EP; Astreinidis A; Li C; Leung YK; Ho SM; Yu JJ
PLoS One; 2020; 15(2):e0228894. PubMed ID: 32078667
[TBL] [Abstract][Full Text] [Related]
22. Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.
Prizant H; Hammes SR
Endocrinology; 2016 Sep; 157(9):3374-83. PubMed ID: 27409646
[TBL] [Abstract][Full Text] [Related]
23. Glutaredoxin-1 promotes lymphangioleiomyomatosis progression through inhibiting Bim-mediated apoptosis via COX2/PGE2/ERK pathway.
Feng Y; Li T; Li Y; Lin Z; Han X; Pei X; Zhang Y; Li F; Yang J; Shao D; Li C
Clin Transl Med; 2023 Jul; 13(7):e1333. PubMed ID: 37478294
[TBL] [Abstract][Full Text] [Related]
24. Mast-Cell Tryptase Release Contributes to Disease Progression in Lymphangioleiomyomatosis.
Babaei-Jadidi R; Dongre A; Miller S; Castellanos Uribe M; Stewart ID; Thompson ZM; Nateri AS; Bradding P; May ST; Clements D; Johnson SR
Am J Respir Crit Care Med; 2021 Aug; 204(4):431-444. PubMed ID: 33882264
[No Abstract] [Full Text] [Related]
25. TSC2 modulates cell adhesion and migration via integrin-α1β1.
Moir LM; Black JL; Krymskaya VP
Am J Physiol Lung Cell Mol Physiol; 2012 Oct; 303(8):L703-10. PubMed ID: 22923640
[TBL] [Abstract][Full Text] [Related]
26. mTORC2 is required for proliferation and survival of TSC2-null cells.
Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP
Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor.
Evans JF; Rue RW; Mukhitov AR; Obraztsova K; Smith CJ; Krymskaya VP
Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31878201
[TBL] [Abstract][Full Text] [Related]
28. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
Makovski V; Haklai R; Kloog Y
Int J Cancer; 2012 Mar; 130(6):1420-9. PubMed ID: 21500191
[TBL] [Abstract][Full Text] [Related]
29. Lymphangioleiomyomatosis and TSC2-/- cells.
Darling TN; Pacheco-Rodriguez G; Gorio A; Lesma E; Walker C; Moss J
Lymphat Res Biol; 2010 Mar; 8(1):59-69. PubMed ID: 20235888
[TBL] [Abstract][Full Text] [Related]
30. Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor gene.
Steagall WK; Pacheco-Rodriguez G; Glasgow CG; Ikeda Y; Lin JP; Zheng G; Moss J
Am J Pathol; 2013 Sep; 183(3):938-50. PubMed ID: 23867796
[TBL] [Abstract][Full Text] [Related]
31. Proapoptotic protein Bim attenuates estrogen-enhanced survival in lymphangioleiomyomatosis.
Li C; Li N; Liu X; Zhang EY; Sun Y; Masuda K; Li J; Sun J; Morrison T; Li X; Chen Y; Wang J; Karim NA; Zhang Y; Blenis J; Reginato MJ; Henske EP; Yu JJ
JCI Insight; 2016 Nov; 1(19):e86629. PubMed ID: 27882343
[TBL] [Abstract][Full Text] [Related]
32. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells.
Tang Y; El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Rosas IO; Moss J; Priolo C; Henske EP
Chest; 2019 Dec; 156(6):1137-1148. PubMed ID: 31299246
[TBL] [Abstract][Full Text] [Related]
33. Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2.
Goncharova EA; Goncharov DA; Spaits M; Noonan DJ; Talovskaya E; Eszterhas A; Krymskaya VP
Am J Respir Cell Mol Biol; 2006 May; 34(5):561-72. PubMed ID: 16424383
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2.
Goldberg AA; Joung KB; Mansuri A; Kang Y; Echavarria R; Nikolajev L; Sun Y; Yu JJ; Laporte SA; Schwertani A; Kristof AS
Oncotarget; 2016 Sep; 7(38):61152-61165. PubMed ID: 27458154
[TBL] [Abstract][Full Text] [Related]
35. SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis.
Tyryshkin A; Bhattacharya A; Eissa NT
Cancer Res; 2014 Apr; 74(7):1996-2005. PubMed ID: 24691995
[TBL] [Abstract][Full Text] [Related]
36. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
Sun Y; Gallacchi D; Zhang EY; Reynolds SB; Robinson L; Malinowska IA; Chiou TT; Pereira AM; Li C; Kwiatkowski DJ; Lee PS; Yu JJ
Am J Respir Cell Mol Biol; 2014 Dec; 51(6):738-49. PubMed ID: 24874429
[TBL] [Abstract][Full Text] [Related]
37. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells.
Lee PS; Tsang SW; Moses MA; Trayes-Gibson Z; Hsiao LL; Jensen R; Squillace R; Kwiatkowski DJ
Am J Respir Cell Mol Biol; 2010 Feb; 42(2):227-34. PubMed ID: 19395678
[TBL] [Abstract][Full Text] [Related]
38. Pulmonary Langerhans Cell Histiocytosis and Lymphangioleiomyomatosis Have Circulating Cells With Loss of Heterozygosity of the TSC2 Gene.
Elia D; Torre O; Vasco C; Geginat J; Abrignani S; Bulgheroni E; Carelli E; Cassandro R; Pacheco-Rodriguez G; Steagall WK; Moss J; Harari S
Chest; 2022 Aug; 162(2):385-393. PubMed ID: 35231481
[TBL] [Abstract][Full Text] [Related]
39. TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis.
Pacheco-Rodriguez G; Steagall WK; Crooks DM; Stevens LA; Hashimoto H; Li S; Wang JA; Darling TN; Moss J
Cancer Res; 2007 Nov; 67(21):10573-81. PubMed ID: 17975002
[TBL] [Abstract][Full Text] [Related]
40. Immune Checkpoint Ligand PD-L1 Is Upregulated in Pulmonary Lymphangioleiomyomatosis.
Maisel K; Merrilees MJ; Atochina-Vasserman EN; Lian L; Obraztsova K; Rue R; Vasserman AN; Zuo N; Angel LF; Gow AJ; Kang I; Wight TN; Eruslanov E; Swartz MA; Krymskaya VP
Am J Respir Cell Mol Biol; 2018 Dec; 59(6):723-732. PubMed ID: 30095976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]